Actinogen anticipates final topline efficacy and safety results for the full 36-week treatment period in November 2026.

Leqembi efficacy doubts in APOE4 subgroups raise regulatory and commercial risks for Eisai and Biogen; see real-world data ...

Boosting the brain's waste-disposal system is increasingly showing promise for Alzheimer's disease, with a study now ...

Doctors say that the number of people with Alzheimer’s disease could potentially triple within the next 25 years. Families of ...

Campbell: Welcome to "Beyond Diagnosis," where we talk with doctors about talking with patients. I'm your host, Glenn ...

The origins of Alzheimer's remain contentious, but a new study suggests the disease may emerge as two key proteins compete ...

A new study suggests that a hormone therapy harvested from human corpses may be linked to a rare, controversial form of ...

Doctors say that the number of people with Alzheimer’s disease could potentially triple within the next 25 years. Families of ...

The idea that two conditions at opposite ends of life might be biologically linked is beginning to upend long-standing ...

In Alzheimer’s disease, brain damage is often linked to a mix of problems, including beta-amyloid buildup, tau pathology, ...

New research reveals flu shots provide unexpected protection beyond seasonal illness prevention.